FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma

The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program.
Source: Food and Drug Administration - Category: American Health Source Type: news